【里昂：升康诺亚-B(02162.HK)目标价至78港元 上半年业绩超预期】智通财经APP获悉，里昂发布研报称，康诺亚-B(02162.HK)上半年业绩超出市场预期，Stapokibart销售额达1.69亿元人民币，高于先前指引的1.5亿元人民币。虽然CM512潜在的二次对外授权机会推动近期股价上升，但公司优先聚焦国内市场的产品开发策略令市场稍为失望。考虑到CM512展现的积极临床进展及成为同类最佳药物的潜力，该行将康诺亚的目标价由65港元上调至78港元，评级由高度确信跑赢大市调整至跑赢大市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.